ReviewCureus2025
Botulinum Toxin Type A in the Management of Plantar Fasciitis: A Step Forward in Pain Relief.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plantar fasciitis is a prevalent cause of heel pain in adults, particularly among the middle-aged population. It is characterized by microtrauma that exceeds the regenerative capacity of the plantar fascia. Although most cases respond well to conservative treatment, such as stretching exercises, orthotic use, and nonsteroidal anti-inflammatory drugs, some cases progress to chronic stages that require second-line therapies, including extracorporeal shockwave therapy, corticosteroid or platelet-rich plasma injections, or surgical plantar fascia release. This review aims to evaluate the efficacy of botulinum toxin type A (BTA) injections in the management of chronic plantar fasciitis. A narrative review was conducted without any date restrictions, covering the period from 1994 to 2025, through databases including PubMed, Scopus, ScienceDirect, and Google Scholar. Included studies focused on patients with plantar fasciitis unresponsive to conservative treatments, using pain and functional outcomes as endpoints. Three randomized controlled trials demonstrated that BTA injections significantly reduced pain and improved function across short, mid-, and long-term follow-ups. BTA acts at the neuromuscular junctions to reduce muscle tone and modulate pain pathways. BTA injections appear to be a safe and effective option for patients with chronic plantar fasciitis unresponsive to first-line therapies. Image-guided injections (ultrasound or electromyographic) are recommended to enhance accuracy. Further research is necessary to establish standardized protocols regarding the injection site, dosage, guidance technique, and reinjection timing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.